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Abstract: The ability to form biofilms contributes significantly to the pathogenesis of many 
microbial infections, including a variety of ocular diseases often associated with the biofilm 
formation on foreign materials. Carvacrol (Car.) is an important component of essential oils 
and recently has attracted much attention pursuant to its ability to promote microbial biofilm 
disruption. In the present study Car. has been encapsulated in poly(DL-lactide-co-glycolide 
(PLGA) nanocapsules in order to obtain a suitable drug delivery system that could represent 
a  starting  point  for  developing  new  therapeutic  strategies  against  biofilm-associated 
infections, such as improving the drug effect by associating an antimicrobial agent with a 
biofilm viscoelasticity modifier. 
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1. Introduction 
Biofilms  are  an  organized  community  of  bacterial  cells  embedded  within  a  hydrated  matrix  of  
self-produced  extracellular  polymeric  substances  (EPS),  which  preferentially  develop  at  solid/liquid 
interfaces.  The  typical  components  of  EPS,  polysaccharides,  proteins  and  DNA,  provide  structural 
stability  and  protection  to  the  biofilm  while  the  presence  of  water  channels  within  the  community 
structure,  resembling  a  primitive  circulatory  system,  ensures  nutrients  and  waste  products  diffusion 
gradients [1,2]. The clinical relevance of these microbial communities is related to their wide ocurrence 
in the developed world together with their ability to cause relapsing infections characterized by chronic 
inflammation, tissue damage and the significant difficulties in their eradication [3,4]. In fact, a wide number of 
diseases,  of  which  bronchopneumonia  in  cystic  fibrosis  patients  [5],  chronic  rhino-sinusitis  [6],  and 
endocarditis [7] represent a short list of examples, result directly from or are associated with biofilm 
growth of bacteria. In addition, owing to their ability to colonize the outer and/or inner surface of 
medical  devices  such  as  catheters  [8] and shunts [9],  respirators, contact lenses [10],  heart valves, 
stents, and orthopedic prostheses [11,12], biofilms are important in that they are responsible for medical 
device-related infections. 
The ability to form biofilms significantly alters important microbial properties: sessile cells show less 
susceptibility to antibiotics and the minimal inhibitory concentration (MIC) and minimal bactericidal 
concentration (MBC) of antibiotics to biofilm-growing bacteria may be up to 10-fold higher compared 
with planktonic bacteria. Moreover, phagocytic host defense mechanism seems incapable of removing 
the biofilm cells protected by the EPS matrix [13–15]. The extraordinary tolerance displayed by cells in 
the  biofilm  towards  antimicrobials  and  the  difficulties  encountered  in  eradication  of  biofilm-related 
infections have been ascribed to a combination of factors, such as high levels of metabolically active and 
growing cells at the biofilm surface and low or no growth in the centre giving rise to a subpopulation of 
persister cells [16,17], high mutation frequency of biofilm-growing bacteria allowing the emergence of 
antibiotic resistance [18], and the presence of the EPS matrix that, being rich in antibiotic-inactivating 
enzymes  and  efflux  pumps,  plays  the  role  of  a  diffusion  barrier  [19].  There  is,  hence,  widespread 
recognition  that  alternative  strategies  or  more  effective  agents  exhibiting  activity  against  biofilm-
growing  microorganisms  are  required  in  order  to  face the unmet medical needs for effective novel 
antibacterial agents. In this regard, Car. [2-methyl-5-(1-methylethyl)phenol], the main component of 
several essential oils, attracted considerable interest for its wide spectrum of antimicrobial activity [20]. 
Importantly, it has been reported that Car. can inhibit the growth of preformed biofilms and to interfere 
with biofilm formation [21–24]. More recently, Nostro and coworkers reported the ability of Car. (1% 
v/v) to significantly reduce S. aureus and S. epidermidis biofilm biomass and cultivable cell numbers 
altering the dense matrix of the biofilm and the cell morphology [25]. 
A great contribution to the improvement of the therapies for biofilm-related diseases is expected with 
the application of nanotechnology to the pharmaceutical sciences. Owing to their tunable size, increased 
suspendability, surface tailorability that allows interactions with biological systems at the molecular level 
[26], nanoparticulate devices could diffuse into the mucus environment surrounding the biofilm colonies 
and there exploit the local and controlled release of the anti biofilm ingredient increasing its residence 
time and effectiveness [27–29]. Notably, Cheow and coworkers reported the preparation of levofloxacin-
loaded poly(DL-lactide-co-glycolide) (PLGA) and poly(caprolactone) (PLC) nanoparticles and showed that, Int. J. Mol. Sci. 2011, 12                       
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to be effective against E. coli biofilm cells, the formulation must ensure a biphasic extended release 
profile with an initial fast release providing high antibiotic concentrations for the biofilm eradication, 
followed  by  slower  antibiotic  extended  release  able  to  minimize  biofilm  growth  and  infection 
exacerbation  [30].  Recently,  Keawchaoon  described  the  preparation  of  carvacrol-loaded  chitosan 
nanoparticles with antimicrobial activity against planktonic S. aureus, B. cereus and E. coli cells [31]. 
The present research, in order to combine the anti biofilm activity of Car. with the excellent delivery 
features of nanotechnology devices and the optimal biocompatibility of PLGA polymers [32], focuses 
on the fabrication of carvacrol-loaded PLGA nanocapsules. The nanodevices have been fabricated by 
the  solvent  displacement  method,  characterized  by  dynamic  light  scattering  (DLS),  zeta  potential 
measurements, and transmission electron microscopy (T.E.M.), and in terms of encapsulation efficiency 
(EE%),  drug  loading  capacity  (DL%)  and  in  vitro  release  profile.  Finally,  the  effects  of  Car.  and 
carvacrol-loaded nanocapsules (Car.-Nps) on the viscoelastic features of S. epidermidis ATCC 35984 
biofilms  grown  under  dynamic  conditions  have  been  investigated  by  rheological  measurements.  A 
cone/plate rheometer was used to measure the viscoelastic properties of the staphylococcal biofilms 
produced. This technique affords the precise monitoring of shear stress and strain acting on the sample [33], 
and provides the opportunity to elucidate, at a macroscopic level, the ability of Car. to destabilize the 
architecture of the dense matrix in which biofilm cells are embedded. 
2. Results and Discussion 
2.1. Preparation and Characterization of Car.-Nps 
In the present work Car.-Nps were conveniently prepared in a good yield (80%) by the solvent 
displacement method. Owing to its lipophilic nature Car. was encapsulated with satisfying EE% and 
DL% (Table 1). More precisely, this method allows the formation of spherical nanocapsules where the 
oily core composed of Car., considered to be a volatile molecule (vapor pressure is 0.0232 mmHg at  
25 °C), is entrapped and retained in a thin dense wall formed by PLGA polymer and phosphatidylcholine. 
Examination by T.E.M. confirmed the presence of nanocapsules characterized by electron-dense walls 
(Figure 1a,b). The individual particles exhibited an approximately spherical shape and a quite variable 
diameter. The nanocapsules tend to cluster on the grid, and showed a compact/thick layer, formed by 
PLGA and phosphatidylcholine (Figure 1a,b), surrounding the less electrondense and thin core of Car. 
reservoir (Figure 1c). 
The  formulation  was  able  to  undergo  the  freeze-drying  process  yielding  spherical  Car.-Nps 
characterized by a relatively narrow size distribution and a mean hydrodynamic diameter (209.8  7.2 nm, 
Table 1), that could allow the diffusion of the particles through the mucus layers present on the surface 
of anatomical sites more frequently subjects of biofilm infections, such as lung airways, sinuses, eyes, 
and gastrointestinal tract. In fact, having a diameter in the range of 200 nm is one of the requisite for 
nanoparticulate devices to reach the surface of mucosal districts covered by this critical barrier [27,28]. Int. J. Mol. Sci. 2011, 12                       
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Table 1. Characteristics of the Car.-Nps formulation. Data are expressed as mean  SD (n = 3). 
Particle size 
(nm) 
  Polydispersity    Zeta potential 
(mV) 
  DL%    EE% 
209.8  7.2    0.260  0.013    −18.99  3.01    21    26 
Figure 1. Electron micrographs showing groups of two or more nanoparticles at different 
magnifications (1a and 1b). In (1c), high magnification (×140 k) of a Car.-Np. Scale bars:  
(a) 0.5 m; (b) 0.2 m; (c) 50 nm. 
 
2.2. In Vitro Drug Release 
The  in  vitro  release  profile  of  Car.-Nps  was  investigated  in  phosphate  buffer  solution,  pH  7.4 
containing 0.5% Tween 80 (PBST) and at 37  0.5 °C. The total drug amount inside the nanocapsules 
was kept below 10% of the drug solubility limit in PBS in order to ensure sink conditions. The in vitro 
release behavior of Car.-Nps presented as the cumulative percentage release is shown in Figure 2. Drug 
release occurred with an initial “burst” release followed by a slower release due to the concentration 
gradient.  Car.-Nps  show  a  60%  release  after  3  h,  and  approach  to  completeness  after  
24 h with approximately 95% of Car. released. The considerable initial fast release of Car. from the 
PLGA nanocapsules might be ascribed to the physicochemical properties of the encapsulated drug. In 
fact,  Car.,  having  a  log  Po/w  of  3.64  will  partition  into  the  lipophilic  matrix  of  the  thin  polymeric 
membrane  surrounding  the  inner  compartment  of  the  carriers  and,  owing  to  its  water  solubility  of  
0.83 mg/mL, could diffuse with high rate toward the aqueous outer phase [34]. 
Figure  2.  Cumulative Car. release from PLGA nanocapsules in PBS pH 7.4  containing 
0.5% Tween 80 at 37 ± 0.5 °C (n = 3). 
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Importantly, Car. is reported to exert its antimicrobial and biofilm-destabilization effects within the 
first 3 h after cell exposition [25], thus, Car.-Nps, being characterized by a “burst” effect in their drug 
release kinetic, could ensure adequate Car. concentration soon after their administration in order to 
exert its antimicrobial effect. 
2.3. Biofilm Growth and Rheological Tests 
Rheometry is a well-established technique for measuring properties of viscoelastic samples, and it has 
the  advantage  that  shear  stresses  and  strain  acting  on  the  sample  are  precisely  monitored.  The 
rheological properties measured are shown in Table 2. All the samples tested were grown directly on 
the rheometer measuring plate in order to preserve their structure, and under a continuous flow rate to 
better reproduce the in vivo conditions (See experimental section and Figure 3). 
Table 2. Rheological characterization of the S. epidermidis ATCC 35984 biofilms. Data are 
expressed as mean  SD (n = 5). 
Sample  LVR 
(Pa) 
η0 (Pa s)  Je0 (Pa
−1)  λ (min)  G′ (Pa) 
1  G′′ (Pa) 
1  y (Pa) 
2 
Bio  1–10  (1.1  0.2)  
× 10
6 
(1.1  0.3)  
× 10
−3 
21.9  6.2  (1.3  0.3)  
× 10
3 
(1.3  0.5) 
× 10
2 
(2.3  0.3)  
× 10
2 
Bio + 
Car. 
1–10  (6.9  0.6)  
× 10
5 a 
(2.5  0.5)  
× 10
−3 
21.6  4.4  (9.3  1.5)  
× 10
2 
(0.9  0.1) 
× 10
2 
(1.5  0.5)  
× 10
2 
Bio + 
Car.-Np 
1–10  (5.5  1.7)  
× 10
5 a 
(7.9  2.8)  
× 10
−3 a,b 
25.5  7.3  (6.1  1.2)  
× 10
2 a 
(0.6  0.1) 
× 10
2 a 
(1.3  0.6)  
× 10
2 
1.  shear  stress  ()  1.0  Pa  satisfying  the  linear viscoelasticity: angular frequency (ω) varied from 0.1 to  
10 Hz. 2.  range 1.0–400 Pa, ω = 1.0 Hz. 
a p < 0.05 compared with Bio. 
b p < 0.05 compared to Car. 
Figure 3. Flow system apparatus. 
 
Samples were divided into biofilms not exposed to Car. (Bio), biofilms treated with Car. itself (Bio + 
Car.), and biofilms treated with Car.-Nps (Bio + Car.-Nps), and showed a linear viscoelastic range Int. J. Mol. Sci. 2011, 12                       
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(LVR). The region was characterized by stress-strain linear proportionality and by constant values of 
the elastic (G′) and the viscous (G″) moduli, starting from 1.0 Pa up to 10.0 Pa and in the frequency 
range 0.1–10 Hz. Biofilms from 48 h growth in dynamic conditions (Figure 3, see experimental section: 
Biofilm preparation) displayed, from a macroscopic point of view, a compact structure which correlates 
with the viscoelastic behavior observed during the rheological tests. These findings are in agreement 
with the results reported in the literature for biofilms of other bacterial species [35–43] where the creep 
and recovery curves of bacterial biofilms showed the typical time-dependent behavior of viscoelastic 
materials having a gel-like structure. It is observed that both biofilms treated either with Car. or Car.-
Nps  showed  a  statistically  significant  reduction  in  the  values  of  the  steady-flow  viscosity  when 
compared with biofilm alone; this finding allows us to speculate a possible role of Car. in triggering 
structural modifications on the EPS matrix of bacterial biofilms. Similarly, the equilibrium compliance, 
Je0, a measure of the elasticity of viscoelastic materials at short times, [44] was reduced by the presence 
of Car., but the data are significant only for Car.-Nps. 
Rheological measurements in the dynamic mode at a constant shear stress indicated a considerable 
elasticity and mechanical stability for the investigated biofilms and confirmed the gel-like behavior with 
the G′ dominating the G′′ by one order of magnitude and exhibiting little frequency dependence over the 
range  of  angular  frequencies  tested.  Biofilms  exposed  to  Car.  were  still  characterized  by  
gel-like  structure  and  behavior,  but  showed  lower  values  of  G′ and G′′ with Car.-Nps significantly 
affecting the magnitude of both the moduli. These new mechanical properties of the biofilm treated with 
Car.-Nps reflect alterations in the architecture of the biofilm and correspond to a fluidification of the 
EPS matrix that could potentially enable or enhance the penetration of antimicrobial agents into the 
deep  core  of  the  biofilm,  where the persister cells are located. These cells are characterized by an 
absent/reduced metabolism that makes them tolerant of the action of the majority of the antimicrobial 
agents [45]; thus Car., which exerts its activity on structural and functional properties of cell membranes 
independently of the cell status, [25] may play a crucial role against the pool of persister cells that in 
most cases represent the main obstacle to an effective biofilm eradication. 
Oscillation stress sweeps in the shear stress range of 1.0–400 Pa at the fixed frequency of 1.0 Hz 
were performed to identify the yield point (y) of the biofilms. Although the procedure to identify the y 
provides  results  influenced  by  the  experimental  condition  used  (operative  frequencies  influence  the 
results), the y values might provide a means to quantify the strength with which biofilms adhere to solid 
surfaces at the solid-liquid interfaces. All the tested biofilms showed high values of y indicating a strong 
ability to adhere to the stainless steel surfaces. Car. treatment seems unable to induce a statistically 
significant reduction of the strength with which preformed biofilms adhere to the measuring plates. Car. 
effectiveness  is  probably  more  evident  at  the  early  stage of biofilm formation, when the adherence 
capacity  of  planktonic  cells  represents  a  major  step  in  the  sessile  colony  
formation [46]. In our experiments, instead, S. epidermidis ATCC 35984 biofilms were exposed to the 
action  of  Car.  at  the  late  stage  of  their  development,  when  the  adhesion  process  to  solid  surfaces  
is complete. 
Biofilms produced in different laboratories are greatly heterogeneous [47], but a commonality of the 
elastic relaxation times (λ, the time scale separating solid and fluid behavior) of different biofilms can be Int. J. Mol. Sci. 2011, 12                       
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observed. Indeed the biofilms’ elastic relaxation times found in our measurements are in accordance 
with the mean value of 18 min reported by Shaw et al. for a wide sample of biofilms (Table 2) [39]. 
3. Experimental Section 
3.1. Materials 
PLGA (D,L-lactide 50: glycolide 50, inherent viscosity within 0.15–0.25 dL/g) with free carboxyl 
end-groups  was  purchased  from  Lactel  Absorbable  Polymers  (Pelham,  USA).  Soy  lecithin 
(phosphatidylcholine-enriched fraction, Epikuron 200), was a kind gift of Cargill Inc (Italy). Carvacrol, 
acetone, Pluronic
® F-68, membrane dialysis (molecular weight cut-off 12,400), Tween
® 80, and HPLC 
grade methanol were purchased from Sigma-Aldrich (Milan, Italy).  
3.2. Preparation of Nanocapsules 
Nanocapsules containing carvacrol were prepared using the solvent displacement process described 
by Fessi et al. [48] Briefly, PLGA (55 mg), Epikuron 200 (65 mg), Car. (244 mg) were dissolved in 
acetone (12.5 mL), and the resulting solution poured, under moderate magnetic stirring, into 25 mL of 
an  aqueous  solution  of  Pluronic
®  F68  5%  (w/v).  Following  10  min  of  stirring,  the  volume  of 
nanocapsules  dispersion  was  concentrated  to  10  mL  under  reduced  pressure.  Separation  of  
non-encapsulated compounds, as well as removal of the exceeding surfactant was performed by dialysis 
technique  introducing  the  suspension  containing  the  nanocapsules  (10  mL)  in  a  dialysis  tube 
hermetically sealed and dialyzing at 37 °C against 3 × 1000 mL of deionized water for 24 h under 
magnetic stirring. Next, the samples collected were freeze-dried during 24 h to obtain a fine powder of 
nanoparticles. All samples were prepared and purified in triplicate. The recovery of nanocapsules was 
calculated as the ratio of the amount of recovered freeze-dried nanoparticles to the total amount of 
polymer and drug added. 
3.3. Characterization of Car.-Nps 
The  size,  size  distribution  and  Zeta  potential  of  reconstituted  nanocapsules-freeze-dried  were 
measured using a Brookhaven (90PLUS BI-MAS) digital correlator equipped with a He-Ne (è Ne o N2) 
laser operating at wavelength of 660.0 nm and at the scattering angle of 90°. All measurements were 
performed at 25 °C and performed at least in triplicate. 
3.4. Preparation and Analysis of Car.-Nps by T.E.M. 
Sample  dispersions  were  dropped  onto  a  copper  grid  pre-coated  with  carbon,  and  dried  under 
reduced pressure prior to T.E.M. observation. Samples were then examined with a Morgagni Series 
268D electron microscope (FEI Company, Brno, Czech Republic), equipped with Megaview III digital 
camera at an accelerating voltage of 100 kV. Int. J. Mol. Sci. 2011, 12                       
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3.5. Determination of Car. Loading 
The Car. loading was determined quantifying the drug extracted from the nanocapsules as reported 
elsewhere [49]. Briefly, 10 mg of dried nanocapsules was dissolved in 5 mL of acetone, stirred for  
10 min and sonicated for 20 min. Next, the dispersion was filtered (membrane filter pore size 0.22 μm) 
and the resulting clear solution was analyzed by HPLC for Car. content using a Waters 1525 binary 
pump equipped with a Waters 2996 photodiode array detector and a Waters Symmetry C18 RP column 
(4.6  ×  150  mm,  5  μm).  A  mixture  of  water  and  methanol  (30:70)  was  used  as  eluent  (flow  rate  
1.0 mL/min, detection wavelength 274.5 nm). Calibration was done with standard dissolved in acetone. 
The experiment was performed in triplicate. DL% and EE% of Car. were calculated from Equations (1) 
and (2), respectively: 
100
es nanocapsul produced of mass
carvacrol ed encapsulat of mass
DL%     (1)  
100
carvacrol added of mass
carvacrol ed encapsulat of mass
EE%     (2)  
3.6. In Vitro Drug Release 
The dialysis bag diffusion technique was used to study the in vitro drug release of Car.-Nps [50]. 
Freeze-dried  nanocapsules  were  re-suspended  in  PBS  and  aliquots  were  placed  in  dialysis  tubes 
(cellulose  membrane,  molecular  weight  cut-off  12,000),  hermetically  sealed,  and  immersed  into  the 
dissolution medium [PBS, pH 7.4 containing Tween
® 80 0.5% (PBST)]. The total drug amount inside 
the nanocapsules was kept below 10% of the drug solubility limit in order to ensure sink conditions. 
The entire system was kept at 37 ± 0.5 °C with continuous magnetic stirring at 40 rpm. The dialysis 
tubes were collected from the dissolution medium at predetermined time intervals and assayed for Car. 
content as reported above. Briefly, 0.5 mL of suspension containing the nanocapsules were dissolved in 
4.5  mL  of  acetone,  stirred  for  10  min  and  sonicated for 20 min.  Next, the dispersion was filtered 
(membrane filter pore size 0.22 μm) and the resulting clear solution was analyzed by HPLC for Car. 
content. The cumulative percentage of Car. released from the nanocapsules at a certain time interval 
was calculated by Equation (3): 
Cumulative % carvacrol released = 100 – (% carvacrol remaining)  (3) 
3.7. Biofilm Preparation 
The  reference  strain  Staphylococcus  epidermidis  ATCC  35984  (biofilm  producer)  [51]  was  the 
microorganism used for the experiments. For the biofilm preparation, a bacterial colony was cultured 
overnight at 37 °C in Tryptic Soy Broth (TSB) (CA; Oxoid Ltd, Italy), then diluted 1:10 (v/v) in TSB 
plus 0.25% of glucose (TSBG) for 2 h at 37 °C in an orbital shaker at 160 r.p.m.. The refreshed broth 
culture was adjusted to OD600 0.25 (ca. 3 × 10
8 CFU mL
−1) in TSBG and inoculated on the rheometer 
plate for the biofilm formation. The biofilm was grown directly on the rheometer plate surface, in order 
to preserve its structure intact in the flow system apparatus (Figure 3). After a bacterial attachment Int. J. Mol. Sci. 2011, 12                       
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period of 4 h on the rheometer plate in static condition at 37 °C, an orbital shaker was activated at 40 
r.p.m., and a peristaltic pump was used to provide a continuous flow of sterile 1/10
th strength of TSB 
supplemented with 0.25% glucose, at the rate of 60 mL h
−1 [41], for 48 h at 37 °C. After 48 h of biofilm 
growth, the flow was stopped and the mature biofilm was washed with sterile PBS and treated with 
1/10
th strength of TSBG (10 mL) containing Car. or Car.-Nps (Car. final concentration 0.25% v/v) for 6 
h, in an orbital shaker at 40 r.p.m.. This concentration represents the dose of 8 MIC, as previously 
determined [24]. The control was treated with 1/10
th strength of TSBG, in the same conditions. 
3.8. Rheological Tests 
The viscoelastic properties of bacterial biofilms were evaluated using a Haake M.A.R.S. II Thermo 
Scientific modular rheometer equipped with a cone and plate sensor system as reported previously [51]. 
Briefly,  the  low  non-rotating  element  that  received  the  sample  was  a  stainless  steel  plate  (Din 
No.1.4841). To prevent dehydration of the biofilm, the sample sandwiched between the cone, and the 
plate was surrounded by 10 mL of sterile PBS at 37 °C. In order to minimize the ‘squeezing G’ of water 
out of the macropores and channels of the biofilm, the rate by which the upper sensor reached the 
measurement position was controlled so that the normal force acting on the sample did not exceed the 
value  of  0.1  N.  The  samples  were  allowed  to  undergo  an  ‘adjustment’  period  of  5  min  after  
loading [40]. All tests were carried out at the controlled temperature of 37  0.3 °C, with the aid of a 
Haake Phoenix (Thermo Electron Corporation) thermo-controller system. The RheoWin software 3.61 
(Thermo Fisher Scientific) was used for data evaluation. Creep and recovery tests were performed, 
applying a constant shear stress (τ) for 300 s followed by a 300 s recovery period (τ = 0); the resulting 
shear strain (γ) was measured over time (t). These tests were performed at several different τ (allowing 
the samples to undergo an adjustment period of 300 s between each test), in order to identify the linear 
viscoelastic range (LVR) of the samples, where γ was directly proportional to τ. Dynamic tests were 
carried out in order to estimate the elastic (G′) and the viscous (G″) moduli of the biofilms, and for the 
determination of their LVR. A series of oscillation frequency sweep tests at shear stress in the range 
1.0–10.0 Pa, across a frequency range from 0.1 to 10 Hz (previously identified as the frequency range 
satisfying the linear viscoelasticity for all the evaluated biofilms), was performed for each sample, and 
the complex shear viscosity (η*), the elastic and the viscous moduli were measured as a function of 
frequency. Oscillation stress sweeps were carried out in the shear stress range 1.0–400 Pa at the fixed 
frequency of 1.0 Hz to evaluate the yield points of the biofilms with y value being identified as the 
lowest stress value to which G′ become dependent on stress amplitude. The measurements were carried 
out in the LVR, as otherwise the results would be dependent on the experimental details and not unique 
to the material [44]. 
3.9. Data analysis and Statistics 
Obtained data were expressed as the mean ± standard error of the mean (SEM) and compared by 
one-way ANOVA followed by Tukey's test. Differences were considered significant at P < 0.05. Int. J. Mol. Sci. 2011, 12                       
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4. Conclusions 
The  aim  of  this  study  was  to  design  polymeric  nanocapsules  loaded  with  the  poorly  soluble 
antimicrobial  agent  carvacrol.  Assembling  the  results  presented,  it  can  be  concluded  that  carvacrol 
encapsulation into PLGA nanocapsules was accomplished with good drug loading and encapsulation 
efficiency.  The  obtained  particles  had  a  spherical  shape  with  a  hydrodynamic  diameter  of  about  
210 nm, which could enable their diffusion through mucus layers present on the surface of anatomical 
sites.  Electron  microscopy  revealed  that  the  nanocapsules  were  characterized  by  an  oily  core  of 
carvacrol  surrounded  by  a  compact  thin  polymeric  wall.  Rheological  tests  revealed  the  ability  of 
carvacrol loaded nanocapsules to alter the properties of preformed staphylococcal biofilms: treatment 
with carvacrol loaded nanocapsules produced a considerable reduction in the elasticity and mechanical 
stability of preformed biofilms that could enable the penetration of antimicrobial agents into the deep 
core  of  bacterial  biofilms.  In  conclusion,  these  new  nanodevices  merit  further  investigation  as  the 
delivery system of antimicrobial agents due to the unique possibility of co-encapsulate, in addition to 
carvacrol, a further antibacterial agent. In fact, the oily core formed by carvacrol, would act as a drug 
reservoir of the additional antibacterial agent opportunely encapsulated during the formulation procedure. 
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